tRNA-Ala-CGC-3 is a target of the Dopamine- and cAMP-regulated phosphoprotein (DARPP-32) protein, a critical player in Huntington’s disease pathogenesis, and functional studies using its inhibitor have validated this interaction. The gene discussed is PPP1R1B; the disease is Huntington disease.